With a deal for the digoxin portfolio of Poland's Nobilus, C2 Pharma will have two supplies of API for making the sometimes difficult-to-get drug.…
Merck KGaA says it will invest €1 billion in its headquarters site in Darmstadt, Germany, as part of a five-year agreement reached with workers there.
CDMO Thermo Fisher Scientific is investing $150 million to expand biologics and sterile manufacturing at one site in the U.S. and two in Italy.
Lilly plans a $91 million plant expansion in Indianapolis, and a $7 million tax abatement tied to the project has generated some debate.
Mylan is recalling a chemo drug and Hospira a commonly used solution because potentially dangerous particulate has been discovered in vials.
Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.
Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.
The FDA has picked apart the process of a Jubilant solid-dose plant in India and criticized it for repeating mistakes.
Lupin has indicated it has received another FDA warning letter as regulatory issues continue to pile up for the Indian drugmaker.
Merck has served as the sole supplier of an important drug for years, and now the company says it can't quite keep up.